Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE (U300) HOE901
Sponsor:   Sanofi
Recruiting - verified March 2015

Abu Dhabi Sleep Apnea (ADSA) Study

Condition:   Sleep Apnoea
Intervention:   Other: Questionnaire
Sponsor:   Imperial College London Diabetes Centre
Recruiting - verified March 2015

Feel4Diabetes-study

Conditions:   Obesity;   Type 2 Diabetes
Intervention:   Behavioral: Feel4Diabetes-intervention
Sponsors:   Harokopio University;   National Institute for Health and Welfare, Finland;   University Ghent;   Technische Universität Dresden;   National and Kapodistrian University of Athens;   International Diabetes Federation;   Universidad de Zaragoza;   Medical University of Varna;   University of Debrecen;   Extensive Life Oy
Not yet recruiting - verified March 2015

Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Momordica charantia;   Drug: Placebo
Sponsor:   University of Guadalajara
Recruiting - verified March 2015

Placement of Hydrophilic TiZr Implants in Diabetic Patients

Condition:   Diabetes Mellitus
Interventions:   Device: 4.1/10.0mm Titanium-Z well-controlled diabetic controls;   Device: 4.1/10.0mm Titanium-Zirconi Not well-controlled diabetics
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting - verified March 2015

The GRADE Capillary Blood Collection Pilot Study

Condition:   Type 2 Diabetes
Intervention:   Procedure: Capillary HbA1c collection
Sponsors:   GRADE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2015

Nutrition, Exercise and Muscle Metabolism in Obesity

Condition:   Obesity
Intervention:   Other: Exercise
Sponsors:   University of Birmingham;   Allen Foundation
Not yet recruiting - verified March 2015

Influence of Regular Exercise and Detraining on Metabolic and Emotional Parameters in Diabetic Individuals

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Exercise
Sponsor:   University of Campinas, Brazil
Completed - verified March 2015

Variable Interval Versus Set Interval Aflibercept for DME

Conditions:   Cystoid Macular Edema;   Diabetic Macular Edema
Intervention:   Drug: Intravitreal Aflibercept Injection
Sponsors:   California Retina Consultants;   Regeneron Pharmaceuticals
Not yet recruiting - verified March 2015

Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)

Conditions:   Bariatric Surgery Candidate;   Diabetes
Interventions:   Procedure: Sleeve Gastrectomy;   Procedure: Roux-en-Y Gastric Bypass;   Procedure: Biliopancreatic Diversion with Duodenal Switch;   Other: Medical management
Sponsors:   Laval University;   Johnson & Johnson Medical Products;   Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Recruiting - verified March 2015

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GLWL-01, Part A;   Drug: Placebo, Part A;   Drug: GLWL-01, Part B;   Drug: Placebo, Part B;   Drug: GLWL-01, Part C;   Drug: Placebo, Part C
Sponsor:   GLWL Research Inc.
Recruiting - verified March 2015

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: ASP8232;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Recruiting - verified March 2015

Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2

Conditions:   Diabetes Mellitus;   Local Anesthesia
Interventions:   Procedure: L+C maxillary anesthesia;   Procedure: L+C mandibular anesthesia;   Procedure: L+E maxillary anesthesia;   Procedure: L+E mandibular anesthesia
Sponsor:   University of Belgrade
Enrolling by invitation - verified March 2015

Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics

Conditions:   Diabetes Mellitus, Type 2;   Nutrition Disorders;   Obesity;   Body Weight;   Metabolic Syndrome x;   Metabolic Diseases
Interventions:   Other: High animal protein diet group;   Other: High plant protein diet group
Sponsors:   German Institute of Human Nutrition;   Ministry of Food and Agriculture, Germany;   Clinical Ernst von Bergmann, Potsdam;   University Hospital Tuebingen;   Institute of Gain Processing IGV GmbH, Potsdam
Enrolling by invitation - verified March 2015

A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Conditions:   Diabetes Mellitus;   Diabetes Mellitus Complications;   Gastroparesis
Interventions:   Drug: RM-131;   Drug: Placebo
Sponsor:   Rhythm Pharmaceuticals, Inc.
Recruiting - verified March 2015

Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: Abbott Sensor Based Glucose Monitoring System-Professional
Sponsor:   Abbott Diabetes Care
Recruiting - verified March 2015

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified March 2015

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Linagliptin;   Other: Placebo;   Drug: Empagliflozin
Sponsor:   Profil Institut für Stoffwechselforschung GmbH
Not yet recruiting - verified March 2015

Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride
Sponsors:   Kansai Electric Power Hospital;   Saiseikai Noe Hospital Osaka
Recruiting - verified March 2015

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified March 2015

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2963016;   Drug: LANTUS®;   Drug: Oral Antihyperglycemic Medication
Sponsors:   Eli Lilly and Company;   Boehringer Ingelheim
Recruiting - verified March 2015

An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes

Condition:   Hypertension
Intervention:  
Sponsors:   Abbott;   Monitor Medikal Araştırma ve Danışmanlık Tic.Ltd.Şti (MonitorCRO)
Recruiting - verified March 2015

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR342434;   Drug: insulin lispro;   Drug: insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified March 2015

Mind-motor Exercise in Older Adults With Type 2 Diabetes and Self-reported Cognitive Complaints

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Square-stepping exercise;   Behavioral: Device: smartphone application (HealtheBrain)
Sponsor:   Lawson Health Research Institute
Recruiting - verified March 2015

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Bydureon;   Drug: Placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified March 2015

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified February 2015

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified March 2015

Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients

Conditions:   Hypertension;   Obesity;   Type 2 Diabetes Mellitus
Interventions:   Drug: Azilsartan 40 mg.;   Drug: Azilsartan 80 mg
Sponsor:   Hospital General de México Dr. Eduardo Liceaga
Recruiting - verified September 2014

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Exenatide matching placebo
Sponsor:   AstraZeneca
Recruiting - verified March 2015

A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: lifestyle modification instructional and motivational sessions
Sponsors:   Medidata Solutions;   Miami Research Associates
Completed - verified March 2015

Phase 3 28 Week Study and 24 Week Extension to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Condition:   Diabetes Mellitus
Interventions:   Drug: Exantide with Dapagliflozin;   Drug: Exentide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified March 2015

The Inova Type 2 Diabetes Mellitus Study

Condition:   Diabetes, Type 2
Interventions:   Drug: Glargine;   Drug: NPH
Sponsor:   Inova Health Care Services
Not yet recruiting - verified March 2015

Mobile Unit Screening of Pathologies Associated With Chronic Diseases - Feasibility

Conditions:   Chronic Obstructive Pulmonary Disease;   Type II Diabetes;   Atherosclerosis
Interventions:   Other: Patient recruitment;   Procedure: Mobile team exam
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Recruiting - verified March 2015

EXIT: Prospective Study of the Response to Exercise

Conditions:   Liver Fat;   Type 2 Diabetes
Intervention:   Other: Acute release of irisin after a single exercise session.
Sponsor:   University of Manitoba
Recruiting - verified March 2015

Hypoxia and Exercise in the Elderly

Condition:   Elderly Persons
Interventions:   Other: Hypoxic exercise;   Other: Normoxic Exercise
Sponsors:   Hannover Medical School;   German Diabetes Center
Not yet recruiting - verified March 2015

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified March 2015

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type II
Interventions:   Drug: Placebo;   Drug: PF-06291874;   Drug: PF-06291874;   Drug: PF-06291874;   Drug: PF-06291874
Sponsor:   Pfizer
Recruiting - verified March 2015

The Effects of a Moderate Weight Loss on Insulin Resistance

Condition:   Insulin Resistance
Intervention:   Behavioral: Dietary consultations
Sponsors:   Yale University;   Howard Hughes Medical Institute
Recruiting - verified March 2015

Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: Saxagliptin;   Drug: Placebo
Sponsors:   Phoenix VA Health Care System;   Bristol-Myers Squibb
Recruiting - verified March 2015

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified March 2015

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dulaglutide;   Drug: Placebo;   Drug: Insulin Glargine;   Drug: Metformin
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2015

A Study to Compare the Effect of Double Doses of Long-acting Insulin Therapies in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin Peglispro;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2015

The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes

Condition:   Type 1 Diabetes
Interventions:   Other: Interventional arm-Mediterranean diet;   Other: Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines
Sponsor:   Rabin Medical Center
Recruiting - verified March 2015

Investigating Markers of Energy Metabolism in Pregnant Women With Insulin Resistance

Conditions:   Gestational Diabetes;   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Yale University
Completed - verified March 2015

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin degludec/liraglutide;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified March 2015

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2015

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Glimepiride;   Drug: Metformin;   Drug: Pioglitazone;   Drug: Acarbose;   Drug: Linagliptin;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin Glargine;   Drug: Exenatide once weekly (QW);   Drug: Exenatide twice daily (BID)
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2015

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin glargine/lixisenatide HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Metformin
Sponsor:   Sanofi
Active, not recruiting - verified March 2015

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin glargine/lixisenatide HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Lixisenatide AVE0010;   Drug: Metformin
Sponsor:   Sanofi
Active, not recruiting - verified March 2015

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified March 2015

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified March 2015

Cirrhosis, Effects of TRAnsplantation and Diabetes

Condition:   Liver Cirrhosis
Intervention:  
Sponsor:   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Recruiting - verified March 2014

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified March 2015

Prevalence of Morbidity in Newly Diagnosed type2 Diabetes in Adults

Conditions:   Type2 Diabetes Mellitus;   Complications
Intervention:   Other: no specific treatment
Sponsors:   University of Algiers;   National Institute of public Health, Algeria;   Ain-Taya's hospital, Algiers;   Parnet's teaching Hospital, Algiers;   Mustapha Pacha's teaching hospital, Algiers;   Birtraria's teaching hospital, Algiers;   Bab el Oued's teaching hospital, Algiers
Completed - verified March 2015

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 50 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified March 2015

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified March 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified March 2015

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Albuminuria
Interventions:   Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified March 2015

Diet and Exercise Intervention in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Optimum Lifestyle Intervention;   Behavioral: Standard Care
Sponsors:   Washington University School of Medicine;   National Dairy Council;   American Egg Board
Recruiting - verified March 2015

Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy

Condition:   Diabetes Mellitus
Interventions:   Drug: Bay G5421 Glucobay;   Drug: Metformin
Sponsor:   Bayer
Withdrawn - verified March 2015

Evaluate the Immunogenicity of a Novel Glucagon Formulation

Conditions:   Drug-specific Antibodies;   Hypoglycemia;   Diabetes Mellitus
Interventions:   Drug: Glucagon IN;   Drug: Glucagon IM
Sponsor:   Locemia Solutions ULC
Completed - verified October 2013

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: lixisenatide AVE0010;   Drug: biguanide;   Drug: TZD;   Drug: alpha-GI;   Drug: glinide
Sponsor:   Sanofi
Active, not recruiting - verified March 2015

Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects

Conditions:   Insulin Resistance;   Type 2 Diabetes
Interventions:   Other: mixed meal;   Other: Acute in vivo induced hyperinsulinemia
Sponsor:   Institute for Clinical and Experimental Medicine
Recruiting - verified March 2015

Metabolic Clock Genes During Fasting and After Food Intake in Type 2 Diabetics

Condition:   Type 2 Diabetes
Interventions:   Other: Fasting No Breakfast (NoB);   Other: Yes Breakfast  (YesB)
Sponsor:   Tel Aviv University
Recruiting - verified March 2015

Vitamin D and Type 2 Diabetes Study

Conditions:   Prediabetes;   Type 2 Diabetes
Interventions:   Dietary Supplement: Vitamin D (Cholecalciferol);   Other: Placebo
Sponsors:   Tufts Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2015

GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Acarbose/Metformin (Glucobay M, BAY81-9783)
Sponsor:   Bayer
Withdrawn - verified March 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified March 2015

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

Condition:   Type 2 Diabetes Mellitus With Diabetic Nephropathy
Interventions:   Drug: GKT137831;   Drug: Placebo
Sponsor:   Genkyotex Innovation SAS
Completed - verified March 2015

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2014

EndoBarrier Versus Intragastric Balloon in Obese Diabetic Patients

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Device: EndoBarrier Gastrointestinal Liner;   Device: Easy life balloon
Sponsor:   The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Recruiting - verified March 2015

Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation

Conditions:   Gestational Diabetes;   Type 2 Diabetes;   Glucose Intolerance
Intervention:   Biological: Post-partum oral glucose tolerance test
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Recruiting - verified March 2015

Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Other: CHICA Type 2 Diabetes Module
Sponsors:   Indiana University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2015

The Aboriginal Youth Mentorship Program

Conditions:   Type 2 Diabetes;   Obesity
Intervention:   Behavioral: Aboriginal Youth Mentorship Program
Sponsors:   University of Manitoba;   Manitoba Institute of Child Health;   The Lawson Foundation
Active, not recruiting - verified March 2015

Lifestyle Intervention for Treatment of Diabetes

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Behavioral: Community Lifestyle Weight Loss (LWL);   Behavioral: Diabetes Self Management (DSM)
Sponsors:   Wake Forest School of Medicine ;   National Center on Minority Health and Health Disparities (NCMHD)
Active, not recruiting - verified December 2014

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: lixisenatide (AVE0010);   Drug: placebo
Sponsor:   Sanofi
Active, not recruiting - verified March 2015

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Comparative Effectiveness of Glycemia-lowering Medications
Interventions:   Drug: Sulfonylurea (glimepiride);   Drug: DPP-4 inhibitor (sitagliptin);   Drug: GLP-1 receptor agonist (liraglutide);   Drug: Insulin (glargine)
Sponsors:   GRADE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Heart, Lung, and Blood Institute (NHLBI);   Becton, Dickinson and Company;   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.;   Novo Nordisk A/S;   Hoffmann-La Roche;   Sanofi
Recruiting - verified March 2015

MARLINA - T2DM : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin 5mg
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified March 2015

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Condition:   Type 2 Diabetes
Intervention:   Drug: ITCA 650 (exenatide in DUROS)
Sponsor:   Intarcia Therapeutics
Active, not recruiting - verified March 2015

Inflammation and Glycation in a General Adult Population

Condition:   Inflammation
Intervention:  
Sponsors:   Hospital Clinico Universitario de Santiago;   Medtronic
Recruiting - verified March 2015

Diabetes Nutrition Algorithms - Galactose- and Fiber-induced Metabolic Improvement in the Dietetic Treatment of Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Dietary Supplement: Dietary supplement (4 arms, 2 active, 2 placebo)
Sponsors:   German Institute of Human Nutrition;   Firma Rettenmeier & Söhne (Company);   German Center for Diabetes Research (DZD)
Recruiting - verified March 2015

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Albiglutide + SU;   Drug: Albiglutide + biguanide;   Drug: Albiglutide + glinide;   Drug: Albiglutide + TZD;   Drug: Albiglutide + alpha-glucosidase inhibitor
Sponsor:   GlaxoSmithKline
Completed - verified March 2015

Bariatric Surgeries and Glucose Homeostasis During a Mixed Meal Test

Condition:   Obesity
Interventions:   Procedure: Roux-en-Y-gastric bypass;   Procedure: laparoscopic adjustable gastric banding;   Procedure: laparoscopic sleeve gastrectomy;   Other: diet treatment
Sponsors:   Azienda Ospedaliera Universitaria Integrata Verona;   Universita di Verona
Recruiting - verified August 2012

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified March 2015

Blood Pressure Outcomes With Liraglutide Therapy

Conditions:   Type 2 Diabetes;   Systolic Hypertension
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsors:   Mount Sinai Hospital, Canada;   Novo Nordisk A/S
Completed - verified March 2015

CPAP in Diabetes Type 2 Patients With Sleep Apnea

Conditions:   Diabetes;   Sleep Apnea
Intervention:   Device: CPAP nasal treatment
Sponsor:   Hospital Universitario La Paz
Completed - verified March 2015

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified March 2015

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empaglifozin placebo + Linagliptin placebo;   Drug: Empagliflozin + Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified March 2015

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified March 2015

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo matching with Dapagliflozin;   Drug: Saxagliptin;   Drug: Metformin immediate release (IR)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Completed - verified October 2014

Screening and Risk Factors of Colon Neoplasia

Condition:   Colon Cancer
Interventions:   Other: Stool DNA Test;   Procedure: biopsies of rectal and colon mucosa;   Other: Questionnaires
Sponsor:   Case Comprehensive Cancer Center
Recruiting - verified March 2015

Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Insulin Resistance
Interventions:   Procedure: Roux en Y Gastric Bypass;   Other: Hypocaloric diet
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   American Diabetes Association
Recruiting - verified March 2015

Eye Blood Flow and the Kidney

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Captopril;   Drug: placebo
Sponsor:   Brigham and Women's Hospital
Recruiting - verified March 2015

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2015

Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients

Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsors:   GWT-TUD GmbH;   Bayer
Active, not recruiting - verified March 2015

Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes

Conditions:   Insulin Resistance;   Chronic Heart Failure
Interventions:   Drug: Metformini hydrochloridum (Siofor 1000 tbl, Berlin);   Drug: placebo
Sponsor:   Institute for Clinical and Experimental Medicine
Recruiting - verified March 2015

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified March 2015

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: metformin;   Drug: placebo;   Drug: placebo;   Drug: glimepiride
Sponsor:   Novo Nordisk A/S
Completed - verified March 2015

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified March 2015

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified March 2015

Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2;   Healthy
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified March 2015

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified March 2015

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: liraglutide;   Drug: glimepiride
Sponsor:   Novo Nordisk A/S
Completed - verified March 2015

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified March 2015

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Procedure: Gastric Bypass;   Drug: Exenatide
Sponsor:   Wu Qinan
Recruiting - verified March 2015

Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: PaQ™ continuous subcutaneous insulin infusion (CSII) device
Sponsors:   CeQur Corporation;   International Diabetes Center at Park Nicollet
Completed - verified March 2015

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes

Conditions:   Depression;   Impaired Glucose Tolerance
Interventions:   Other: The Blues Program;   Other: Hey Durham
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institutes of Health Clinical Center (CC)
Active, not recruiting - verified April 2014

Families Defeating Diabetes

Condition:   Diabetes Prevention
Intervention:   Other: FDD program
Sponsor:   Lawson Health Research Institute
Active, not recruiting - verified March 2015

The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors Among Hispanics and African Americans With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes
Intervention:   Drug: Cholecalciferol
Sponsor:   Florida International University
Completed - verified March 2015

Hemoglobin A1c and Immediate Postsurgical Complications Diabetes Type 2

Condition:   Postoperative Complications
Intervention:  
Sponsor:   Hospital Italiano de Buenos Aires
Recruiting - verified March 2015

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: BI1356 low dose;   Drug: BI1356 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified March 2015

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

Conditions:   High Risk Proliferative Diabetic Retinopathy;   Diabetes Mellitus Type I;   Diabetes Mellitus Type II
Interventions:   Procedure: Panretinal Photocoagulation (PRP);   Drug: Intravitreous injection of pegaptanib
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Completed - verified April 2013

Glutathione in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Proteinuria;   Oxidative Stress
Interventions:   Drug: N-acetylcysteine placebo + silibin placebo;   Drug: N-acetylcysteine active + silibin placebo;   Drug: N-acetylcysteine placebo + silibin active;   Drug: N-acetylcysteine active + silibin active;   Drug: N-acetylcysteine active + high-dose silibin active
Sponsors:   Department of Veterans Affairs;   National Center for Complementary and Integrative Health (NCCIH)
Active, not recruiting - verified March 2015

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: linagliptin;   Drug: glimepiride;   Drug: linagliptin placebo;   Drug: glimepride placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified March 2015

Gene x Behavior Interaction in the Look AHEAD Study

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Behavioral: Intensive lifestyle intervention;   Behavioral: Diabetes support and education
Sponsors:   The Miriam Hospital;   Tufts Medical Center;   Brown University
Completed - verified March 2015

A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1[AM3])

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo;   Drug: pioglitazone;   Drug: metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2015

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Completed - verified March 2015

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified March 2015

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects

Condition:   Type 2 Diabetes
Interventions:   Drug: dapagliflozin;   Drug: dapagliflozin;   Drug: dapagliflozin;   Drug: dapagliflozin;   Drug: dapagliflozin;   Drug: dapagliflozin
Sponsor:   AstraZeneca
Completed - verified March 2015

Local Measures to Prevent Diabetes in the Værnes Region.

Conditions:   Diabetes Mellitus Type 2;   Obesity
Intervention:   Behavioral: Behavioural change programme
Sponsor:   Norwegian University of Science and Technology
Recruiting - verified March 2015

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Dapagliflozin Placebo;   Drug: Pioglitazone
Sponsor:   AstraZeneca
Completed - verified March 2015

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Dapagliflozin Placebo
Sponsor:   AstraZeneca
Completed - verified March 2015

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Rifampin
Sponsor:   AstraZeneca
Terminated - verified March 2015

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: Dapagliflozin;   Drug: Metformin XR;   Drug: Glucophage
Sponsor:   AstraZeneca
Completed - verified March 2015

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bumetanide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Completed - verified March 2015

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

Conditions:   Diabetic Nephropathies;   Proteinuria;   Oxidative Stress
Interventions:   Dietary Supplement: N-acetylcysteine;   Dietary Supplement: silibin;   Dietary Supplement: high-dose silibin;   Dietary Supplement: N-acetylcysteine placebo;   Dietary Supplement: silibin placebo
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Center for Complementary and Integrative Health (NCCIH);   Department of Veterans Affairs
Active, not recruiting - verified March 2015

TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Telmisartan 80 mg/d;   Drug: Ramipril 10 mg/d
Sponsor:   University of Erlangen-Nürnberg Medical School
Completed - verified March 2015

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Completed - verified March 2015

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Warfarin;   Drug: Digoxin
Sponsor:   AstraZeneca
Completed - verified March 2015

Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: insulin detemir
Sponsor:   Novo Nordisk A/S
Completed - verified March 2015

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Glimepiride;   Drug: Sitagliptin
Sponsor:   AstraZeneca
Completed - verified March 2015

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: simvastatin;   Drug: Dapagliflozin;   Drug: simvastatin;   Drug: valsartan
Sponsor:   AstraZeneca
Completed - verified March 2015

Renal Mechanism of Action/Splay vs. TmG

Condition:   Diabetes, NOS
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Terminated - verified March 2015

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin;   Drug: Placebo
Sponsor:   AstraZeneca
Completed - verified March 2015

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Metformin XR
Sponsor:   AstraZeneca
Completed - verified March 2015

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsor:   AstraZeneca
Completed - verified March 2015

Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Obesity
Intervention:   Behavioral: 8 weeks individualized training program
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Completed - verified March 2015

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes
Interventions:   Drug: dapagliflozin;   Drug: dapagliflozin;   Drug: dapagliflozin;   Drug: dapagliflozin;   Drug: dapagliflozin;   Drug: placebo;   Drug: metformin
Sponsor:   AstraZeneca
Completed - verified March 2015

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: pramlintide acetate
Sponsor:   AstraZeneca
Completed - verified March 2015

Get CardioSmart

You're Invited